MA49426B1 - Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2 - Google Patents

Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2

Info

Publication number
MA49426B1
MA49426B1 MA49426A MA49426A MA49426B1 MA 49426 B1 MA49426 B1 MA 49426B1 MA 49426 A MA49426 A MA 49426A MA 49426 A MA49426 A MA 49426A MA 49426 B1 MA49426 B1 MA 49426B1
Authority
MA
Morocco
Prior art keywords
antibody fragments
antivenoms
production
high throughput
toxins
Prior art date
Application number
MA49426A
Other languages
English (en)
Other versions
MA49426A1 (fr
Inventor
Canudas Jorge Alejandro González
Ubbelohde Walter Jacob García
Romero Gabriel Rosas
Martínez Vicente Rivera
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of MA49426A1 publication Critical patent/MA49426A1/fr
Publication of MA49426B1 publication Critical patent/MA49426B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne le domaine des produits d’origine biologique basée sur la fragmentation d’anticorps qui s’utilisent pour une immunisation passive afin de neutraliser les toxines présentes dans les venins des animaux vénéneux, notamment un produit biologique dont le principe actif est une combinaison de fragments d’anticorps f(ab')2 et le procédé d’obtention de celui-ci avec un rendement élevé et une meilleure qualité quant à la pureté et à la capacité neutralisante de ces toxines. L'invention décrit également leur purification à partir de plasma hyperimmun par relargage sans crésol, thermocoagulation ni dialyse et par application de techniques d’ultrafiltration avec des paramètres spécifiques pour obtenir des fragments de f(ab')2 de puretés supérieures à 95%.
MA49426A 2017-10-02 2017-10-02 Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2 MA49426B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2017/000115 WO2019070108A1 (fr) 2017-10-02 2017-10-02 Processus à haut rendement pour la production d'antivenins à partir de fragments d'anticorps f(ab') 2

Publications (2)

Publication Number Publication Date
MA49426A1 MA49426A1 (fr) 2021-02-26
MA49426B1 true MA49426B1 (fr) 2022-09-30

Family

ID=65994605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49426A MA49426B1 (fr) 2017-10-02 2017-10-02 Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2

Country Status (5)

Country Link
EP (1) EP3680252A4 (fr)
CO (1) CO2020001084A2 (fr)
MA (1) MA49426B1 (fr)
MX (1) MX2019015360A (fr)
WO (1) WO2019070108A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4814433A (en) 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
CA2163032C (fr) 1993-06-03 2001-02-06 John Landon Fragments d'anticorps a des fins therapeutiques
FI981717A (fi) 1998-08-07 2000-02-08 Borealis As Katalysaattorikomponentti, joka käsittää magnesiumia, titaania, halogeenia ja elektronidonorin, sen valmistus ja käyttö
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
SI1456238T1 (sl) 2001-12-17 2008-08-31 Crucell Holland Bv Proizvodnja f(ab)2 fragmentov v sesalskih celicah
CN101816789B (zh) 2010-04-08 2012-09-05 成都军区疾病预防控制中心军事医学研究所 抗蝰蛇蛇毒冻干血清及制备方法
MX367136B (es) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
CN103864930B (zh) 2014-02-17 2016-08-10 中国人民解放军成都军区疾病预防控制中心 抗中国东亚钳蝎蝎毒F(ab’)2抗体制备及其使用方法

Also Published As

Publication number Publication date
CO2020001084A2 (es) 2020-02-18
EP3680252A1 (fr) 2020-07-15
WO2019070108A1 (fr) 2019-04-11
MX2019015360A (es) 2020-02-07
EP3680252A4 (fr) 2021-04-28
MA49426A1 (fr) 2021-02-26

Similar Documents

Publication Publication Date Title
EA201890039A1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
PE20190261A1 (es) Anticuerpos que reconocen tau
WO2019224711A3 (fr) Anticorps anti-cd33, anticorps bispécifiques anti-cd33/anti-cd3 et leurs utilisations
RU2377254C2 (ru) Мутанты анти-cd40 антитела
BR112019008010A2 (pt) anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica
EA201991099A1 (ru) Антитела против cd73 и их применение
CY1118389T1 (el) Νεα αντισωματα ανταγωνιστων και fab θραυσματα αυτων εναντι του gpvi και χρησεις αυτων
RU2018125624A (ru) Антитела к с5 и способы их применения
RU2017125758A (ru) Антитела к с5 и способы их применения
WO2010056898A3 (fr) Clonage à expression rapide d'anticorps monoclonaux humains de cellules b à mémoire
IN2012DN01328A (fr)
PE20191079A1 (es) Inmunoglobulinas y usos de estas
RU2011142183A (ru) Средство для лечения ревматоидного артрита
RU2017145085A (ru) Анти-pre-s1 hbv антитела
PE20220392A1 (es) Moleculas de union a claudina-6 y usos de las mismas
EA202192108A1 (ru) Непрерывный способ изготовления для изготовления биопрепаратов посредством интеграции процессов получения лекарственного вещества и лекарственного препарата
EA201992516A1 (ru) Способ получения бифункциональных белков и их производных
EA202192907A1 (ru) Моноклональное антитело, которое специфически связывается с gitr
RU2017104638A (ru) Нейтрализующие антитела к вирусу гриппа B и пути их применения
MA49426B1 (fr) Processus à haut rendement pour la production d’antivenins à partir de fragments d’anticorps f(ab') 2
EA201892477A1 (ru) Препараты и способы для обработки фотосинтезирующих организмов и повышения их качества и урожайности с помощью препаратов композитов гликанов
PL435319A1 (pl) Sposób otrzymywania hialuronidazy oraz produkt otrzymany tym sposobem
WO2022034524A3 (fr) Anticorps contre ilt2 et leur utilisation
EA201990364A1 (ru) КРИСТАЛЛИЧЕСКИЕ И СОЛЕВЫЕ ФОРМЫ 7-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И СПОСОБ ИХ ПОЛУЧЕНИЯ
EA202193193A1 (ru) Приготовление прелипосомального лиофилизата аннамицина